Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of 63 cents beat Wall Street’s estimate of 47 cents ...

Pfizer Inc. closed 18.10% below its 52-week high of $31.54, which the company reached on July 30th.

In June 2024, Pfizer's first global chief marketing officer, Drew Panayiotou, left the company after less than two years in the role. Under Panayiotou, last year Pfizer ran its first-ever Super Bowl ...

Shares of Pfizer Inc. PFE slipped 1.21% to $26.20 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...